Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers.
ORKA-001, a long-acting monoclonal antibody targeting IL-23p19, is being investigated for the treatment of patients with Psoriasis.
In the Phase 1 study, ORKA-001 demonstrated an estimated half-life of about 100 days, suggesting the potential for once-yearly dosing, and was well tolerated with a favorable safety profile.
Initial data from the ongoing EVERLAST-A Phase 2a study are expected in the second half of 2026. Oruka also expects to initiate a Phase 2b study of ORKA-001 in patients with plaque psoriasis, dubbed EVERLAST-B, in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.